tm logo
LEADERSHIP IN NANOPHARMACEUTICALS
Dead/Abandoned
ABANDONED - NO STATEMENT OF USE FILED

no statement of use filed

on 17 Mar 2014

Last Applicant/ Owned by

840 Memorial Drive, 5th Floor

Cambridge

MA

02139

Serial Number

85085203 filed on 15th Jul 2010

Registration Number

N/A

Correspondent Address

DAVID EHRLICH

FROSS ZELNICK LEHRMAN & ZISSU, P.C.

866 UNITED NATIONS PLZ

NEW YORK, NY 10017-1822

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

"NANOPHARMACEUTICALS"

LEADERSHIP IN NANOPHARMACEUTICALS

Pharmaceutical preparations for use in the diagnosis and prognosis of oncological diseases or disorders; pharmaceutical preparations for use in the diagnosis, prognosis, and treatment of pre-cancerous diseases or disorders; pharmaceutical preparations for use in the diagnosis and prognosis of malignant cancers or neoplasms; pharmaceutical preparations for use in the diagnosis, prognosis and treatmRead More

Classification Information


Class [001]
Chemical Products


diagnostic and prognostic preparations for clinical or medical laboratory use; diagnostic and prognostic reagents for identifying a disease or disorder and/or the progression of a disease or disorder

Class [005]
Pharmaceutical Products


Pharmaceutical preparations for use in the diagnosis and prognosis of oncological diseases or disorders; pharmaceutical preparations for use in the diagnosis, prognosis, and treatment of pre-cancerous diseases or disorders; pharmaceutical preparations for use in the diagnosis and prognosis of malignant cancers or neoplasms; pharmaceutical preparations for use in the diagnosis, prognosis and treatment of benign cancers or neoplasms; pharmaceutical preparations for use in the diagnosis, prognosis, and treatment of inflammation and inflammatory diseases or disorders; pharmaceutical preparations for use in the diagnosis, prognosis, and treatment of cardiovascular diseases or disorders; pharmaceutical preparations for use in modulating angiogenesis; pharmaceutical preparations, namely, drug delivery systems that contain compounds which facilitate the delivery of a wide range of pharmaceuticals; pharmaceutical preparations, namely, drug delivery systems that contain nanometer scale or nanometer size compounds which facilitate the delivery of a wide range of pharmaceuticals; pharmaceutical preparations, namely, drug delivery systems that contain polymer and/or lipid based compounds for controlled release of a wide range of pharmaceuticals; pharmaceutical preparations for use in the diagnosis and prognosis of oncological diseases or disorders comprising a pharmaceutical included with a nanometer-sized composition which facilitates the delivery and/or the controlled release of the pharmaceutical; pharmaceutical preparations for use in the diagnosis, prognosis and treatment of pre-cancerous diseases or disorders comprising a pharmaceutical included with a nanometer-sized composition which facilitates the delivery and/or the controlled release of the pharmaceutical; pharmaceutical preparations for use in the diagnosis, prognosis and treatment of benign cancers or neoplasms comprising a pharmaceutical included with a nanometer-sized composition which facilitates the delivery and/or the controlled release of the pharmaceutical; pharmaceutical preparations for use in the diagnosis and prognosis of malignant cancers or neoplasms comprising a pharmaceutical included with a nanometer-sized composition which facilitates the delivery and/or the controlled release of the pharmaceutical; pharmaceutical preparations for use in the diagnosis, prognosis, and treatment of inflammation and inflammatory diseases or disorders comprising a pharmaceutical included with a nanometer-sized composition which facilitates the delivery and/or the controlled release of the pharmaceutical; pharmaceutical preparations for use in the diagnosis, prognosis, and treatment of cardiovascular diseases or disorders comprising a pharmaceutical included with a nanometer-sized composition which facilitates the delivery and/or the controlled release of the pharmaceutical

Mark Details


Serial Number

No 85085203

Mark Type

No Service/Collective Mark

Attorney Docket Number

No TPHA 1004940

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
17th Mar 2014ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
17th Mar 2014ABANDONMENT - NO USE STATEMENT FILED
09th Aug 2013NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
08th Aug 2013EXTENSION 5 GRANTED
02th Aug 2013CASE ASSIGNED TO INTENT TO USE PARALEGAL
09th Jul 2013EXTENSION 5 FILED
09th Jul 2013TEAS EXTENSION RECEIVED
30th Jan 2013NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
29th Jan 2013EXTENSION 4 GRANTED
10th Jan 2013TEAS EXTENSION RECEIVED